Abstract
Primary open-angle glaucoma (POAG) is a multifactorial disease. One of the risk factors in POAG is intraocular hypertonia, but the level of intraocular pressure (IOP) does not appear to correlate with the degree of functional deficit in this disease. In fact, visual field defects have been observed in subjects with normal or only slightly elevated IOPs. Current treatment for POAG is normalization of IOP with a beta-blocker. Nevertheless, a number of studies have shown that these agents do not improve the visual fields of patients with POA(;.“.‘,“-“,“’ The actions of beta-blockers on the retinal vasculature may compromise their utility for the treatment of these patients. The purpose of the first study reported here was to determine whether a beta-blocker with intrinsic sympathomimetic activity (ISA), carteolol, would provide greater preservation of visual fields than timolol. The purpose of the second study was to determine whether a relatively specific beta, antagonist, betaxolol, was superior to timolol in visual field preservation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
